サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1392698

肝炎治療薬の世界市場レポート 2024年

Hepatitis Drugs Global Market Report 2024
出版日: 受注後更新 | 発行: The Business Research Company | ページ情報: 英文 200 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
肝炎治療薬の世界市場レポート 2024年
出版日: 受注後更新
発行: The Business Research Company
ページ情報: 英文 200 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 目次
概要

肝炎治療薬市場規模は近年着実に成長しています。2023年の193億4,000万米ドルから2024年には202億8,000万米ドルへと、CAGR4.9％で拡大します。過去の成長は、肝炎ウイルスを標的とする抗ウイルス薬の発見、肝炎の診断技術の進歩、肝炎の世界の負担に対する意識の高まり、肝炎ワクチン接種プログラムの拡大、肝炎のインターフェロンベースの治療法の開発などに起因しています。

様々なタイプの肝炎患者の増加が肝炎治療薬市場の成長を大きく促進しています。様々なタイプの肝炎が異なる治療薬を必要とするため、肝炎治療薬の需要が増加しています。例えば、スイスに本部を置く国際公衆衛生機関である世界保健機関（WHO）によると、2022年6月には2億9,600万人が慢性B型肝炎に感染しており、毎年平均150万人が新たに感染しています。このような肝炎感染者の増加は、必ず肝炎治療薬の必要性と消費量を増加させる。このように、異なるタイプの肝炎の増加は、予測期間における肝炎治療薬の成長を促進すると予想されます。

研究開発への投資の増加は、今後数年間の肝炎治療薬市場の成長を促進すると予想されます。研究開発とは、新しい商品、プロセス、サービスを発見、実験、発明、開発するため、または現在のものを強化するために、企業、機関、組織によって実施される研究業務を指します。研究開発への投資は、財務的成長、社会的改善、企業の成功、持続可能性に大きく貢献し、いくつかの分野における進歩や創造性を促進します。例えば、2023年5月、オーストラリアを拠点とする政府の最高立法府であるオーストラリア議会によると、政府は2022-23年に研究開発に121億米ドルを投資する予定です。これは前年比3.2％増です。したがって、研究開発への投資増が肝炎治療薬市場を牽引しています。

2023年の肝炎治療薬市場で最大の地域は北米です。アジア太平洋は予測期間中に最も急成長する地域となる見込みです。肝炎治療薬市場レポートの対象地域は、アジア太平洋、西欧、東欧、北米、南米、中東、アフリカです。

目次

第1章 エグゼクティブサマリー

第2章 肝炎治療薬市場の特徴

第3章 肝炎治療薬市場の動向と戦略

第4章 肝炎治療薬市場-マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19による市場への影響

第5章 世界の肝炎治療薬市場規模と成長

  • 世界の肝炎治療薬市場の促進要因と抑制要因
    • 市場の促進要因
    • 市場の抑制要因
  • 世界の肝炎治療薬市場規模実績と成長、2018～2023年
  • 世界の肝炎治療薬市場規模と成長予測、2023～2028年、2033年

第6章 肝炎治療薬市場セグメンテーション

  • 世界の肝炎治療薬市場、薬剤クラス別セグメンテーション、実績と予測、2018～2023年、2023～2028年、2033年
  • インターフェロンアルファ
  • HIV NRTI
  • ヌクレオチドポリメラーゼ/NS5A阻害剤の組み合わせ
  • C型肝炎プロテアーゼ/NS5A阻害剤の組み合わせ
  • NS5A阻害剤
  • ヌクレオチドポリメラーゼ阻害剤
  • ヌクレオシド類似体抗ウイルス薬
  • 血小板生成刺激剤
  • 世界の肝炎治療薬市場、投与経路別セグメンテーション、実績と予測、2018～2023年、2023～2028年、2033年
  • 経口
  • 注射
  • 世界の肝炎治療薬市場、流通チャネル別セグメンテーション、実績と予測、2018～2023年、2023～2028年、2033年
  • 病院薬局
  • 小売薬局
  • オンライン薬局
  • 世界の肝炎治療薬市場、用途別セグメンテーション、実績と予測、2018～2023年、2023～2028年、2033年
  • A型肝炎
  • B型肝炎
  • C型肝炎
  • D型肝炎
  • E型肝炎

第7章 肝炎治療薬市場の地域と国分析

  • 世界の肝炎治療薬市場、地域別、実績と予測、2018～2023年、2023～2028年、2033年
  • 世界の肝炎治療薬市場、国別、実績と予測、2018～2023年、2023～2028年、2033年

第8章 アジア太平洋の肝炎治療薬市場

第9章 中国の肝炎治療薬市場

第10章 インドの肝炎治療薬市場

第11章 日本の肝炎治療薬市場

第12章 オーストラリアの肝炎治療薬市場

第13章 インドネシアの肝炎治療薬市場

第14章 韓国の肝炎治療薬市場

第15章 西欧の肝炎治療薬市場

第16章 英国の肝炎治療薬市場

第17章 ドイツの肝炎治療薬市場

第18章 フランスの肝炎治療薬市場

第19章 イタリアの肝炎治療薬市場

第20章 スペインの肝炎治療薬市場

第21章 東欧の肝炎治療薬市場

第22章 ロシアの肝炎治療薬市場

第23章 北米の肝炎治療薬市場

第24章 米国の肝炎治療薬市場

第25章 カナダの肝炎治療薬市場

第26章 南米の肝炎治療薬市場

第27章 ブラジルの肝炎治療薬市場

第28章 中東の肝炎治療薬市場

第29章 アフリカの肝炎治療薬市場

第30章 肝炎治療薬市場の競合情勢と企業プロファイル

  • 肝炎治療薬市場の競合情勢
  • 肝炎治療薬市場の企業プロファイル
    • Gilead Sciences Inc.
    • F. Hoffmann-La Roche Ltd
    • GlaxoSmithKline plc
    • Johnson & Johnson
    • Merck & Co. Inc.

第31章 世界の肝炎治療薬市場の競合ベンチマーキング

第32章 世界の肝炎治療薬市場の競合ダッシュボード

第33章 肝炎治療薬市場における主要な合併と買収

第34章 肝炎治療薬市場の将来展望と可能性分析

第35章 付録

目次
Product Code: r10386

“Hepatitis Drugs Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on hepatitis drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for hepatitis drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The hepatitis drugs market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

  • 1) By Drug Class: Interferon Alphas; HIV NRTIs; Nucleotide Polymerase/NS5A Inhibitor Combinations; Hepatitis C Protease/NS5A Inhibitor Combinations; NS5A Inhibitors; Nucleotide Polymerase Inhibitors; Nucleoside Analogue Antivirals; Thrombopoiesis Stimulating Agents
  • 2) By Route Of Administration: Oral; Injection
  • 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
  • 4) By Application: Hepatitis A; Hepatitis B; Hepatitis C; Hepatitis D; Hepatitis E
  • Companies Mentioned: Gilead Sciences Inc.; F. Hoffmann-La Roche Ltd; GlaxoSmithKline plc; Johnson & Johnson; Merck & Co. Inc.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Hepatitis drugs refer to medications that aggravate liver inflammation. A number of viruses (viral hepatitis), substances, medications, alcohol, certain genetic abnormalities, an overactive immune system that mistakenly assaults the liver (autoimmune hepatitis), and other factors can result in liver inflammation.

The main type of hepatitis drugs interferon alphas, HIV NRTIS, nucleotide polymerase / NS5A inhibitor combinations, hepatitis C protease / NS5A inhibitor combinations, NS5A inhibitors, nucleotide polymerase inhibitors, nucleoside analog antivirals, and thrombopoiesis stimulating agents. The interferon alphas are the innate immune system in response to environmental exposures such as viral infections. Interferon alpha has been developed in different formulations for the treatment but mainly for chronic hepatitis C. The drugs are consumed through oral or injection route of administration and are distributed through channels such as hospital pharmacies, retail pharmacies, and online pharmacies. These drugs are used to treat hepatitis A, hepatitis B, hepatitis C, hepatitis D and hepatitis E.

The hepatitis drugs market research report is one of a series of new reports from The Business Research Company that provides hepatitis drugs market statistics, including hepatitis drugs industry global market size, regional shares, competitors with a hepatitis drugs market share, detailed hepatitis drugs market segments, market trends and opportunities, and any further data you may need to thrive in the hepatitis drugs industry. This hepatitis drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The hepatitis drugs market size has grown steadily in recent years. It will grow from $19. 34 billion in 2023 to $20. 28 billion in 2024 at a compound annual growth rate (CAGR) of 4. 9%. The growth in the historic period can be attributed to discovery of antiviral drugs targeting hepatitis viruses, advances in diagnostic technologies for hepatitis, growing awareness of the global burden of hepatitis, expansion of hepatitis vaccination programs, development of interferon-based therapies for hepatitis.

The hepatitis drugs market size is expected to see steady growth in the next few years. It will grow to $23. 92 billion in 2028 at a compound annual growth rate (CAGR) of 4. 2%. The growth in the forecast period can be attributed to introduction of novel direct-acting antiviral drugs, increasing prevalence of hepatitis infections, rise in government initiatives for hepatitis prevention and treatment, advances in personalized medicine approaches for hepatitis, expansion of access to hepatitis drugs in developing countries. Major trends in the forecast period include transition from interferon-based to interferon-free therapies, development of pan-genotypic antiviral drugs for hepatitis c, integration of non-invasive diagnostic methods for liver fibrosis assessment, exploration of combination therapies for hepatitis b, growing focus on the elimination of viral hepatitis as a public health threat.

The increase in number of cases of different types of hepatitis is significantly driving the growth of the hepatitis drug market. Various types of hepatitis need different drugs for treatment, which increases the demand for hepatitis drugs. For instance, in June 2022, according to the World Health Organization (WHO), a Switzerland based international public health organization, 296 million people had a chronic hepatitis B infection, with an average of 1. 5 million new infections every year. This increasing number of hepatitis infections will invariably increase the need for and consumption of hepatitis drugs. Thus, the increasing number of different types of hepatitis is expected to propel the growth of hepatitis drugs in the forecast period.

The rising investment in research and development is expected to propel the growth of the hepatitis drug market in the coming years. Research and development refer to the research operations carried out by businesses, institutions, or organizations to discover, experiment, invent, and develop new goods, processes, or services, or to enhance current ones. Investments in research and development contribute considerably to financial growth, societal improvement, corporate success, and sustainability, promoting advancement and creativity in several areas. For instance, in May 2023, according to the Parliament of Australia, an Australia-based government supreme legislative branch, the government is going to invest $12. 1 billion in research and development in 2022-23. This is a 3. 2% increase over the previous year. Therefore, the rising investment in research and development is driving the hepatitis drugs market.

New product launches are a significant trend in the hepatitis drugs market. The key players in the hepatitis drugs sector are focusing on launching new products for hepatitis treatments to strengthen their position in the market. For instance, in June 2021, the Malaysian National Pharmaceutical Regulatory Agency (NPRA) issued conditional authorization for a secure and efficient hepatitis C treatment created by the Malaysian Ministry of Health, the non-profit research and development organization Drugs for Neglected Diseases Initiative (DNDi), the Egyptian pharmaceutical company Pharco, the Malaysian pharmaceutical company Pharmaniaga Berhad, and the non-profit organization Medecins Sans Frontieres/Doctors Without Borders (MSF). This is the first HCV medication created through South-South collaboration, as well as with non-profit finance and clinical assistance.

Major companies operating in the hepatitis drug market are focusing on innovative products, such as Vemlidy (tenofovir alafenamide), to better meet the needs of their existing consumers. Vemlidy (Tenofovir alafenamide) is an antiretroviral medicine belonging to the nucleotide reverse transcriptase inhibitor (NRTI) class used to treat HIV (Human Immunodeficiency Virus) and persistent hepatitis B virus infections. For instance, in November 2022, Gilead Sciences Inc., a US-based biopharmaceutical company, announced the approval of Vemlidy (tenofovir alafenamide) at a dose of 25 mg for the treatment of chronic hepatitis B virus infection in pediatric individuals. Vemlidy is a new, targeted tenofovir prodrug used as a once-daily therapy for individuals with persistent HBV infection with compensatory liver disease. It is indicated as a recommended or first-line therapy for individuals with chronic HBV and aggravated liver disease in AASLD and EASL recommendations.

In March 2021, Gilead Sciences, a US-based biopharmaceutical company acquired MYR GmbH for cash consideration of $1. 55 billion (€1. 45 billion). As a result of the acquisition, Gilead leverages the MYR GmbH's new drugs and expansion of the market globally in providing better treatment for hepatitis. MYR GmbH is a Germany-based company that develops inhibitors for chronic hepatitis B and D infections.

Major companies operating in the in the hepatitis drugs market report are Gilead Sciences Inc., F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, Johnson & Johnson, Merck & Co. Inc., Abbott Laboratories, AbbVie Inc., Arbutus Biopharma Corporation, Aspen Pharmacare Holdings Limited, Aurobindo Pharma Limited, Beijing Kawin Technology Share-Holding Co. Ltd., Beximco Pharmaceuticals Ltd., Biocon Limited, Bristol-Myers Squibb Company, Cadila Healthcare Limited, Cipla Limited, Dr. Reddy's Laboratories Ltd., Enanta Pharmaceuticals Inc., Hetero Drugs Limited, Laurus Labs Limited, Lupin Pharmaceuticals Inc., Micro Labs Limited, Mylan N. V., Natco Pharma Limited, Novartis International AG, Roche Holding AG, Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Ltd., Zydus Cadila Healthcare Limited, Vir Biotechnology Inc., Agenus Inc., Genentech Inc., Eisai Pharmaceuticals India Pvt. Ltd.

North America was the largest region in the hepatitis drugs market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hepatitis drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the hepatitis drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain.

The hepatitis drugs market consists of sales of ribavirin, elbasvir-grazoprevir, and glecaprevir-pibrentasvir. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified)).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Table of Contents

1. Executive Summary

2. Hepatitis Drugs Market Characteristics

3. Hepatitis Drugs Market Trends And Strategies

4. Hepatitis Drugs Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Hepatitis Drugs Market Size and Growth

  • 5.1. Global Hepatitis Drugs Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Hepatitis Drugs Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Hepatitis Drugs Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Hepatitis Drugs Market Segmentation

  • 6.1. Global Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Interferon Alphas
  • HIV NRTIs
  • Nucleotide Polymerase/NS5A Inhibitor Combinations
  • Hepatitis C Protease/NS5A Inhibitor Combinations
  • NS5A Inhibitors
  • Nucleotide Polymerase Inhibitors
  • Nucleoside Analogue Antivirals
  • Thrombopoiesis Stimulating Agents
  • 6.2. Global Hepatitis Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Oral
  • Injection
  • 6.3. Global Hepatitis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • 6. 4. Global Hepatitis Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hepatitis A
  • Hepatitis B
  • Hepatitis C
  • Hepatitis D
  • Hepatitis E

7. Hepatitis Drugs Market Regional And Country Analysis

  • 7.1. Global Hepatitis Drugs Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Hepatitis Drugs Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Hepatitis Drugs Market

  • 8.1. Asia-Pacific Hepatitis Drugs Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Hepatitis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8. 4. Asia-Pacific Hepatitis Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Hepatitis Drugs Market

  • 9.1. China Hepatitis Drugs Market Overview
  • 9.2. China Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Hepatitis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9. 4. China Hepatitis Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Hepatitis Drugs Market

  • 10.1. India Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Hepatitis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Hepatitis Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Hepatitis Drugs Market

  • 11.1. Japan Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.2. Japan Hepatitis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Hepatitis Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Hepatitis Drugs Market

  • 12.1. Australia Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Hepatitis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Hepatitis Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Hepatitis Drugs Market

  • 13.1. Indonesia Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Hepatitis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Hepatitis Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Hepatitis Drugs Market

  • 14.1. South Korea Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.2. South Korea Hepatitis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Hepatitis Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Hepatitis Drugs Market

  • 15.1. Western Europe Hepatitis Drugs Market Overview
  • 15.2. Western Europe Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Hepatitis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15. 4. Western Europe Hepatitis Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Hepatitis Drugs Market

  • 16.1. UK Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Hepatitis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Hepatitis Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Hepatitis Drugs Market

  • 17.1. Germany Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Hepatitis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Hepatitis Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Hepatitis Drugs Market

  • 18. 5. France Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18. 6. France Hepatitis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18. 7. France Hepatitis Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Hepatitis Drugs Market

  • 19. 9. Italy Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.10. Italy Hepatitis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.11. Italy Hepatitis Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Hepatitis Drugs Market

  • 20.13. Spain Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.14. Spain Hepatitis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.15. Spain Hepatitis Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Hepatitis Drugs Market

  • 21.1. Eastern Europe Hepatitis Drugs Market Overview
  • 21.2. Eastern Europe Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Hepatitis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21. 4. Eastern Europe Hepatitis Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Hepatitis Drugs Market

  • 22.1. Russia Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Hepatitis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Hepatitis Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Hepatitis Drugs Market

  • 23.1. North America Hepatitis Drugs Market Overview
  • 23.2. North America Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Hepatitis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23. 4. North America Hepatitis Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Hepatitis Drugs Market

  • 24.1. USA Hepatitis Drugs Market Overview
  • 24.2. USA Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Hepatitis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24. 4. USA Hepatitis Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Hepatitis Drugs Market

  • 25.1. Canada Hepatitis Drugs Market Overview
  • 25.2. Canada Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Hepatitis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25. 4. Canada Hepatitis Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Hepatitis Drugs Market

  • 26.1. South America Hepatitis Drugs Market Overview
  • 26.2. South America Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Hepatitis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26. 4. South America Hepatitis Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Hepatitis Drugs Market

  • 27.1. Brazil Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Hepatitis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Hepatitis Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Hepatitis Drugs Market

  • 28.1. Middle East Hepatitis Drugs Market Overview
  • 28.2. Middle East Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Hepatitis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28. 4. Middle East Hepatitis Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Hepatitis Drugs Market

  • 29.1. Africa Hepatitis Drugs Market Overview
  • 29.2. Africa Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Hepatitis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29. 4. Africa Hepatitis Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Hepatitis Drugs Market Competitive Landscape And Company Profiles

  • 30.1. Hepatitis Drugs Market Competitive Landscape
  • 30.2. Hepatitis Drugs Market Company Profiles
    • 30.2.1. Gilead Sciences Inc.
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1. 4. Financial Performance
    • 30.2.2. F. Hoffmann-La Roche Ltd
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2. 4. Financial Performance
    • 30.2.3. GlaxoSmithKline plc
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3. 4. Financial Performance
    • 30.2. 4. Johnson & Johnson
      • 30.2. 4.1. Overview
      • 30.2. 4.2. Products and Services
      • 30.2. 4.3. Strategy
      • 30.2. 4. 4. Financial Performance
    • 30.2. 5. Merck & Co. Inc.
      • 30.2. 5.1. Overview
      • 30.2. 5.2. Products and Services
      • 30.2. 5.3. Strategy
      • 30.2. 5. 4. Financial Performance

31. Global Hepatitis Drugs Market Competitive Benchmarking

32. Global Hepatitis Drugs Market Competitive Dashboard

33. Key Mergers And Acquisitions In The Hepatitis Drugs Market

34. Hepatitis Drugs Market Future Outlook and Potential Analysis

  • 34.1 Hepatitis Drugs Market In 2028 - Countries Offering Most New Opportunities
  • 34.2 Hepatitis Drugs Market In 2028 - Segments Offering Most New Opportunities
  • 34. 3 Hepatitis Drugs Market In 2028 - Growth Strategies
    • 34.3.1 Market Trend Based Strategies
    • 34.3.2 Competitor Strategies

35. Appendix

  • 35.1. Abbreviations
  • 35.2. Currencies
  • 35.3. Historic And Forecast Inflation Rates
  • 35. 4. Research Inquiries
  • 35. 5. The Business Research Company
  • 35. 6. Copyright And Disclaimer